Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Valirx Plc (VAL.LN)

Valirx Plc (VAL.LN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Valirx Plc D6 Thane Road MediCity Nottingham Nottingham NG90 6BH GBR

https://www.valirx.com P: 115-784-0026

Description:

ValiRx PLC is a UK-based biopharmaceutical company. It mainly engages in developing technologies and products in oncology therapeutics and diagnostics. The area of focus for the company is the treatment of cancer and associated biomarkers, specializing in epigenomic and genetic analysis. The company develops therapeutics across fields in oncology and has a portfolio of products in the pipeline which include GeneICE for Silencing Rebellious Genes, VAL201 for prostate cancer, VAL401 for lung cancer, VAL301, BC201, CLX001, and other drug candidates in their different stages of development.

Key Statistics

Overview:

Market Capitalization, $K 1,654
Shares Outstanding, K 132,349
Annual Sales, $ 10 K
Annual Net Income, $ -2,038 K
% of Insider Shareholders 30.07%
% of Institutional Shareholders 35.40%

Growth:

1-Year Return -89.29%
3-Year Return -97.64%
5-Year Return -92.27%

Per-Share Information:

Next Earnings Date N/A
Earnings Per Share ttm -0.02
Dividend Payout Ratio 0.00%
Most Recent Split 1-125 on 04/06/20

VAL.LN Ratios

Ratio
Price/Earnings ttm N/A
Price/Earnings forward N/A
Return-on-Equity % -49.01%
Return-on-Assets % -50.82%
Profit Margin % -21,226.05%
Debt/Equity 0.00
Price/Sales 152.04
Price/Book 0.43
Book Value/Share 0.03
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar